Buscar
14/06/2022
Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease
Aranha, MR, Fortea, J, Carmona-Iragui, M. Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease. NEUROLOGY. 2022; 98(24)DOI:10.1212/WNL.0000000000200704. PMID:35470138. IF:9.900(Q1/1D).
14/06/2022
The European Heart Journal: fulfilling the mission
Crea, F, Badimon, L, Berry, C, De Caterina, R, Elliott, PM, Hatala, R, Libby, P, Linde, C, Tybjaerg-Hansen, A. The European Heart Journal: fulfilling the mission. EUROPEAN HEART JOURNAL. 2022; 43(23)DOI:10.1093/eurheartj/ehac171. PMID:35512309. IF:39.300(Q1/1D).
09/06/2022
Vitamin D Binding Protein and Renal Injury in Acute Decompensated Heart Failure
Diaz-Riera, E, Garcia-Arguinzonis, M, Lopez, L, Garcia-Moll, X, Badimon, L, Padro, T. Vitamin D Binding Protein and Renal Injury in Acute Decompensated Heart Failure. Frontiers in Cardiovascular Medicine. 2022; 9DOI:10.3389/fcvm.2022.829490. PMID:35757319. IF:3.600(Q2/5D).
09/06/2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).